415 related articles for article (PubMed ID: 33925695)
1. Next Generation Therapeutics for the Treatment of Myelofibrosis.
Tremblay D; Mascarenhas J
Cells; 2021 Apr; 10(5):. PubMed ID: 33925695
[TBL] [Abstract][Full Text] [Related]
2. Novel treatments for myelofibrosis: beyond JAK inhibitors.
Tremblay D; Mesa R
Int J Hematol; 2022 May; 115(5):645-658. PubMed ID: 35182376
[TBL] [Abstract][Full Text] [Related]
3. New Treatments for Myelofibrosis.
Tremblay D; Mesa R
Curr Treat Options Oncol; 2023 Feb; 24(2):61-75. PubMed ID: 36640223
[TBL] [Abstract][Full Text] [Related]
4. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
Chifotides HT; Bose P; Masarova L; Pemmaraju N; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):210-223. PubMed ID: 34840087
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials.
Tremblay D; Hoffman R
Expert Opin Emerg Drugs; 2021 Dec; 26(4):351-362. PubMed ID: 34875179
[TBL] [Abstract][Full Text] [Related]
6. 'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.
Assi R; Verstovsek S; Daver N
Curr Opin Hematol; 2017 Mar; 24(2):115-124. PubMed ID: 28072602
[TBL] [Abstract][Full Text] [Related]
7. Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition.
Komrokji R; Verstovsek S
Expert Rev Hematol; 2012 Dec; 5(6):631-41. PubMed ID: 23216593
[TBL] [Abstract][Full Text] [Related]
8. Treatment of anemia in myelofibrosis: focusing on novel therapeutic options.
Arslan Davulcu E; Oğuz MB; Kılıç E; Eşkazan AE
Expert Opin Investig Drugs; 2024 Jan; 33(1):27-37. PubMed ID: 38073183
[TBL] [Abstract][Full Text] [Related]
9. [Novel therapeutics in myeloproliferative neoplasms: beyond JAK inhibitors].
Edahiro Y
Rinsho Ketsueki; 2023; 64(9):970-980. PubMed ID: 37793873
[TBL] [Abstract][Full Text] [Related]
10. Novel therapies for myelofibrosis.
Stein BL; Cervantes F; Giles F; Harrison CN; Verstovsek S
Leuk Lymphoma; 2015; 56(10):2768-78. PubMed ID: 25860240
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy of Myelofibrosis.
Tremblay D; Marcellino B; Mascarenhas J
Drugs; 2017 Sep; 77(14):1549-1563. PubMed ID: 28791654
[TBL] [Abstract][Full Text] [Related]
12. The future of JAK inhibition in myelofibrosis and beyond.
Mascarenhas JO; Cross NC; Mesa RA
Blood Rev; 2014 Sep; 28(5):189-96. PubMed ID: 25043171
[TBL] [Abstract][Full Text] [Related]
13. Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond.
Harrison CN; McLornan DP
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):489-497. PubMed ID: 29222297
[TBL] [Abstract][Full Text] [Related]
14. Investigational non-JAK inhibitors for chronic phase myelofibrosis.
Bankar A; Gupta V
Expert Opin Investig Drugs; 2020 May; 29(5):461-474. PubMed ID: 32245330
[TBL] [Abstract][Full Text] [Related]
15. Kinase signaling and targeted therapy for primary myelofibrosis.
Yang Q; Crispino JD; Wen QJ
Exp Hematol; 2017 Apr; 48():32-38. PubMed ID: 28043820
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
Arana Yi C; Tam CS; Verstovsek S
Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
[TBL] [Abstract][Full Text] [Related]
17. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
18. SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis.
Chifotides HT; Masarova L; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):219-231. PubMed ID: 36797153
[TBL] [Abstract][Full Text] [Related]
19. Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.
Waksal JA; Mascarenhas J
Curr Hematol Malig Rep; 2022 Oct; 17(5):140-154. PubMed ID: 35984598
[TBL] [Abstract][Full Text] [Related]
20. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
